SCHEMBL5116019

SCHEMBL5116019

Cc1sc2nc(-n3cncn3)nc(NCc3ccccc3)c2c1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 4/20 0.47
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46
RXFP1 Q9HBX9 2/20 0.45
GAA P10253 1/20 0.45
PLA2G1B P04054 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
RAB9A P51151 2/20 0.41
HTT P42858 5/20 0.41
MAPK1 P28482 4/20 0.40
PDE5A O76074 1/20 0.39
PTGS1 P23219 1/20 0.39
TBXAS1 P24557 1/20 0.39
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118514 0.90 GAA (0.46) ALDH1A1KDM4ELMNASMN1; SMN2ADORA2A
SCHEMBL5124544 0.90 PDE5A (0.39) ALDH1A1KDM4ELMNASMN1; SMN2ADORA2A
SCHEMBL5115157 0.85 ADORA2A (0.42) ALDH1A1KDM4ELMNASMN1; SMN2ADORA2A
SCHEMBL5119048 0.84 PDE5A (0.42) ALDH1A1KDM4ELMNASMN1; SMN2ADORA2A
SCHEMBL5118379 0.84 ALDH1A1 (0.48) ALDH1A1KDM4ELMNASMN1; SMN2ADORA2A
SCHEMBL5127705 0.83 TNF (0.42) ALDH1A1KDM4ELMNAADORA2AADORA1
SCHEMBL5129121 0.83 ESR1 (0.47) ALDH1A1LMNARXFP1RAB9APDE5A
SCHEMBL5117638 0.82 ALDH1A1 (0.47) ALDH1A1KDM4ELMNASMN1; SMN2ADORA2A
SCHEMBL5125462 0.82 ALDH1A1 (0.42) ALDH1A1KDM4ELMNASMN1; SMN2ADORA2A
SCHEMBL5125465 0.82 PDE5A (0.58) ALDH1A1KDM4ELMNASMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ALDH1A1 1055/4885KDM4E 257/4885LMNA 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.